Glycosylation: Impact, control and improvement during therapeutic protein production

Critical Reviews in Biotechnology

Volumn 34, Issue 4, 2014, Pages 281-299

  Costa, Ana Rita ^a   Rodrigues, Maria Elisa ^a   Henriques, Mariana ^a   Oliveira, Rosário ^a   Azeredo, Joana ^a  

^a UNIVERSITY OF MINHO   (Portugal)

Author keywords

Analytical methodologies; Culture parameters; Expression system; Glycoengineering; Mammalian cells; Process development

Indexed keywords

ANIMAL CELL CULTURE; BIOACTIVITY; GLYCOSYLATION; MAMMALS;

ANALYTICAL METHODOLOGY; CULTURE PARAMETERS; EXPRESSION SYSTEM; GLYCOENGINEERING; MAMMALIAN CELLS; PROCESS DEVELOPMENT;

RECOMBINANT PROTEINS;

DOLICHOL; GLYCAN; GLYCOPEPTIDE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOSACCHARIDE; PROTEIN; RECOMBINANT PROTEIN; SIALIC ACID DERIVATIVE;

AFFECT; AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; BACTERIUM; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL CULTURE; CELL DENSITY; CELL GROWTH; CELL METABOLISM; CELL TYPE; CELL VIABILITY; CHEMICAL STRUCTURE; CLEARANCE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONSENSUS SEQUENCE; CULTURE MEDIUM; ELECTROSPRAY MASS SPECTROMETRY; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; GENE EXPRESSION SYSTEM; GOLGI COMPLEX; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOST CELL; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IMMUNOGENICITY; INSECT CELL; MAMMAL CELL; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLIC ENGINEERING; NONHUMAN; NUTRIENT; PLANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; QUALITY CONTROL; REGULATORY MECHANISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SITE DIRECTED MUTAGENESIS; SOLUBILITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; YEAST; ANIMAL; BIOREACTOR; CHEMISTRY; GENETICS; GLYCOSYLATION; METABOLISM; PROTEIN ENGINEERING;

MAMMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOREACTORS; CELLS, CULTURED; GLYCOSYLATION; HUMANS; PLANTS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; YEASTS;

EID: 84911418415     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2013.793649     Document Type: Review

References (250)

1. Abe H, Takaoka Y, Chiba Y, et al. (2009). Development of valuable yeast strains using a novel mutagenesis technique for the effective production of therapeutic glycoproteins. Glycobiology, 19, 428-36.
2. Abès R, Teillaud J-L. (2010). Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals, 3, 146-57.
3. Altmann F, Staudacher E, Wilson IBH, März L. (1999). Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconjugate J, 16, 109-23.
4. Andersen D. 2004. Cell culture effects on the glycosylation of therapeutic proteins. Bioprocess International. IBC LifeSciences.
5. Andersen DC, Goochee CF. (1994). The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins. Curr Opin Biotechnol, 5, 546-9.
6. Andersen DC, Reilly DE. (2004). Production technologies for monoclonal antibodies and their fragments. Curr Opin Biotechnol, 15, 456-62.
7. Baker K, Flatman S, Birch J. (2007). Product characterization from gene to therapeutic product. Medicines from animal cell culture. Chichester, UK: John Wiley & Sons, Ltd., 433-42.
8. Baker KN, Rendall MH, Hills AE, et al. (2001). Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol Bioeng, 73, 188-202.
9. Bañó-Polo M, Baldin F, Tamborero S, et al. (2011). N-glycosylation efficiency is determined by the distance to the C-terminus and the amino acid preceding an Asn-Ser-Thr sequon. Protein Sci, 20, 179-86.
10. Bardor M, Faveeuw C, Fitchette A-C, et al. (2003). Immunoreactivity in mammals of two typical plant glyco-epitopes, core a(1, 3)-fucose and core xylose. Glycobiology, 13, 427-34.
11. Beck A, Wagner-Rousset E, Bussat M, et al. (2008). Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol, 9, 482-501.
12. Bertozzi C, Rabuka D. (2009). Structural basis of glycan diversity. In: Varki A, Cummings R, Esko J, et al., eds. Essentials of glycobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 601-16.
13. Bigge J, Patel T, Bruce J, et al. (1995). Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal Biochem, 230, 229-38.
14. Birch JR, Racher AJ. (2006). Antibody production. Adv Drug Delivery Rev, 58, 671-85.
15. Bobrowicz P, Davidson RC, Li H, et al. (2004). Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology, 14, 757-66.
16. Bollati-Fogolín M, Forno G, Nimtz M, et al. (2005). Temperature reduction in cultures of hGM-CSF-expressing CHO cells: effect on productivity and product quality. Biotechnol Prog, 21, 17-21.
17. Bork K, Horstkorte R, Weidemann W. (2009). Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosyn-thetic pathway. J Pharm Sci, 98, 3499-508.
18. Borys MC, Linzer DIH, Papoutsakis ET. (1993). Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells. Nat Biotech, 11, 720-4.
19. Borys MC, Linzer DIH, Papoutsakis ET. (1994). Ammonia affects the glycosylation patterns of recombinant mouse placental lactogen-I by chinese hamster ovary cells in a pH-dependent manner. Biotechnol Bioeng, 43, 505-14.
20. Boyd P, Lines A, Patel A. (1995). The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol, 32, 1311-18.
21. Brooks S. (2004). Appropriate glycosylation of recombinant proteins for human use. Mol Biotechnol, 28, 241-55.
22. Brooks S. (2009). Strategies for analysis of the glycosylation of proteins: current status and future perspectives. Mol Biotechnol, 43, 76-88.
23. Brunner D, Frank J, Appl H, et al. (2010). Serum-free cell culture: the serum-free media interactive online database. ALTEX, 27, 53-62.
24. Bulleid N, Bassel-Duby R, Freedman R, et al. (1992). Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation. Biochem J, 286, 275-80.
25. Burgener A, Butler M. (2006). Medium development. In: Ozturk S, Hu W-S, eds. Cell culture technology for pharmaceutical and cell-based therapies. Boca Raton, FL: CRC Press, 41-80.
26. Butler M, ed. (2004). Animal cell culture and technology. Oxford, UK: BIOS Scientific Publishers, 256 p.
27. Butler M. (2005). Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol, 68, 283-91.
28. Butters TD. (2002). Control in the N-linked glycoprotein biosynthesis pathway. Chem Biol, 9, 1266-8.
29. Campbell MP, Royle L, Radcliffe CM, et al. (2008). GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics, 24, 1214-16.
30. Castilho A, Gattinger P, Grass J, et al. (2011). N-Glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology, 21, 813-23.
31. Castro P, Ison A, Hayter P, Bull A. (1995). The macroheterogeneity of recombinant human interferon-gamma produced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium. Biotechnol Appl Biochem, 21, 87-100.
32. Cereghino JL, Cregg JM. (2000). Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev, 24, 45-66.
33. Chenu S, Grégoire A, Malykh Y, et al. (2003). Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy. Biochim Biophys Acta, Gen Subj, 1622, 133-44.
34. Chiba Y, Jigami Y. (2007). Production of humanized glycoproteins in bacteria and yeasts. Curr Opin Chem Biol, 11, 670-6.
35. Chotigeat W, Watanapokasin Y, Mahler S, Gray PP. (1994). Role of environmental conditions on the expression levels, glycoform pattern and levels of sialyltransferase for hFSH produced by recombinant CHO cells. Cytotechnology, 15, 217-21.
36. Chu L, Robinson DK. (2001). Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol, 12, 180-7.
37. Chung CH, Mirakhur B, Chan E, et al. (2008). Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1, 3-galactose. N Engl J Med, 358, 1109-17.
38. Clark KJR, Chaplin FWR, Harcum SW. (2004). Temperature effects on product-quality-related enzymes in batch CHO cell cultures producing recombinant tPa. Biotechnol Prog, 20, 1888-92.
39. Crispin M, Bowden TA, Coles CH, et al. (2009). Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J Mol Biol, 387, 1061-6.
40. Crowell CK, Grampp GE, Rogers GN, et al. (2007). Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng, 96, 538-49.
41. Cruz HJ, Freitas CM, Alves PM, et al. (2000). Effects of ammonia and lactate on growth, metabolism, and productivity of BHK cells. Enzyme Microb Technol, 27, 43-52.
42. Cummings RD, Etzler ME. (2009). Antibodies and lectins in glycan analysis. In: Varki A, Cummings R, Esko J, eds. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
43. Dalpathado DS, Desaire H. (2008). Glycopeptide analysis by mass spectrometry. Analyst, 133, 731-8.
44. Dasgupta S, Navarrete A-M, Bayry J, et al. (2007). A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4 T lymphocytes. Proc Nat Acad Sci, 104, 8965-70.
45. Davies J, Jiang LY, Pan L-Z, et al. (2001). Expression of GnTIII in recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcyRIII. Biotechnol Bioeng, 74, 288-94.
46. De Pourcq K, De Schutter K, Callewaert N. (2010). Engineering of glycosylation in yeast and other fungi: current state and perspectives. Appl Microbiol Biotechnol, 87, 1617-31.
47. Dempski Jr RE, Imperiali B. (2002). Oligosaccharyl transferase: gatekeeper to the secretory pathway. Curr Opin Chem Biol, 6, 844-50.
48. Dingermann T. (2008). Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J, 3, 90-7.
49. Domann PJ, Pardos-Pardos AC, Fernandes DL, et al. (2007). Separation-based glycoprofiling approaches using fluorescent labels. Proteomics, 7, 70-6.
50. Durocher Y, Butler M. (2009). Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol, 20, 700-7.
51. Dwek MV, Rawlings SL. (2006). Breast cancer proteomics using two-dimensional electrophoresis: studying the breast cancer proteome. Meth Mol Med, 120, 231-43.
52. Egrie JC, Browne JK. (2001). Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer, 84, 3-10.
53. Elliott S, Lorenzini T, Asher S, et al. (2003). Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotech, 21, 414-21.
54. Erbayraktar S, Grasso G, Sfacteria A, et al. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Nat Acad Sci, 100, 6741-6.
55. Fenn J, Mann M, Meng C, et al. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science, 246, 64-71.
56. Ferrara C, Brünker P, Suter T, et al. (2006a). Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterol-ogous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng, 93, 851-61.
57. Ferrara C, Stuart F, Sondermann P, et al. (2006b). The Carbohydrate at FcgRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem, 281, 5032-6.
58. Fukuta K, Abe R, Yokomatsu T, et al. (2000a). Remodeling of sugar chain structures of human interferon-g. Glycobiology, 10, 421-30.
59. Fukuta K, Yokomatsu T, Abe R, et al. (2000b). Genetic engineering of CHO cells producing human interferon-y by transfection of sialyl-transferases. Glycoconjugate J, 17, 895-904.
60. Galili U, Rachmilewitz E, Peleg A, Flechner I. (1984). A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med, 160, 1519-31.
61. Garcia-Casado G, Sanchez-Monge R, Chrispeels MJ, et al. (1996). Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins. Glycobiology, 6, 471-7.
62. Gawlitzek M, Ryll T, Lofgren J, Sliwkowski MB. (2000). Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. Biotechnol Bioeng, 68, 637-46.
63. Gawlitzek M, Valley U, Nimtz M, et al. (1995). Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions. J Biotechnol, 42, 117-31.
64. Geigert J. (2004). The challenge of CMC regulatory compliance for biopharmaceuticals. New York: Springer, 386 p.
65. Geng M, Zhang X, Bina M, Regnier F. (2001). Proteomics of glycoproteins based on affinity selection of glycopeptides from tryptic digests. J Chromatogr, B: Biomed Sci Appl, 752, 293-306.
66. Gennaro LA, Salas-Solano O. (2008). On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies. Anal Chem, 80, 3838-45.
67. Goh JSY, Zhang P, Fai Chan K, et al. (2010). RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of normal GnT I in these mutants enhances sialylation of recombinant erythropoietin. Metab Eng, 12, 360-8.
68. Goldman MH, James DC, Rendall M, et al. (1998). Monitoring recombinant human interferon-gamma N-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells. Biotechnol Bioeng, 60, 596-607.
69. Gomord V, Faye Lc. (2004). Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol, 7, 171-81.
70. Goochee CF, Gramer MJ, Andersen DC, et al. (1991). The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Nat Biotech, 9, 1347-55.
71. Gramer MJ, Goochee CF. (1993). Glycosidase activities in chinese hamster ovary cell lysate and cell culture supernatant. Biotechnol Prog, 9, 366-73.
72. Gu X, Wang DIC. (1998). Improvement of interferon-y sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosa-mine. Biotechnol Bioeng, 58, 642-8.
73. Guile GR, Rudd PM, Wing DR, et al. (1996). A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem, 240, 210-26.
74. Guile GR, Wong SYC, Dwek RA. (1994). Analytical and preparative separation of anionic oligosaccharides by weak anion-exchange high-performance liquid chromatography on an inert polymer column. Anal Biochem, 222, 231-5.
75. Hahn TJ, Goochee CF. (1992). Growth-associated glycosylation of transferrin secreted by HepG2 cells. J Biol Chem, 267, 23982-7.
76. Hamilton SR, Gerngross TU. (2007). Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol, 18, 387-92.
77. Harcum SW (2006). Protein glycosylation. In: Ozturk S, Hu W-S, eds. Cell Culture Technology for Pharmaceutical and Cell-based Therapies. Boca Raton (FL): CRC Press.
78. Hayter PM, Curling EM, Baines AJ, et al. (1992). Glucose-limited chemostat culture of chinese hamster ovary cells producing recombinant human interferon-gamma. Biotechnol Bioeng, 39, 327-35.
79. Hayter PM, Curling EMA, Gould ML, et al. (1993). The effect of the dilution rate on CHO cell physiology and recombinant interferon-y production in glucose-limited chemostat culture. Biotechnol Bioeng, 42, 1077-85.
80. Helenius A, Aebi M. (2001). Intracellular functions of N-glycans. Science, 291, 2364-9.
81. Helenius J, Aebi M. (2002). Transmembrane movement of dolichol linked carbohydrates during N-glycoprotein biosynthesis in the endoplasmic reticulum. Semin Cell Dev Biol, 13, 171-8.
82. Hellwig S, Drossard J, Twyman RM, Fischer R. (2004). Plant cell cultures for the production of recombinant proteins. Nat Biotech, 22, 1415-22.
83. Hemström P, Irgum K. (2006). Hydrophilic interaction chromatography. J Sep Sci, 29, 1784-821.
84. Hirano K, Macmillan D, Tezuka K, et al. (2009). Design and synthesis of a homogeneous erythropoietin analogue with two human complextype sialyloligosaccharides: combined use of chemical and bacterial protein expression methods. Angew Chem, Int Ed, 48, 9557-60.
85. Hodoniczky J, Zheng YZ, James DC. (2005). Control of recombinant monoclonal antibody effector functions by fc n-glycan remodeling in vitro. Biotechnol Prog, 21, 1644-52.
86. Hossler P, Khattak SF, Li ZJ. (2009). Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology, 19, 936-49.
87. Hsu K-L, Mahal LK. (2006). A lectin microarray approach for the rapid analysis of bacterial glycans. Nat Protoc, 1, 543-9.
88. Huang Y-M, Hu W, Rustandi E, et al. (2010). Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Prog, 26, 1400-10.
89. Huang Y, Mechref Y, Novotny MV. (2001). Microscale nonreductive release of o-linked glycans for subsequent analysis through MALDI mass spectrometry and capillary electrophoresis. Anal Chem, 73, 6063-9.
90. Huhn C, Selman MHJ, Ruhaak LR, et al. (2009). IgG glycosylation analysis. Proteomics, 9, 882-913.
91. Iida S, Misaka H, Inoue M, et al. (2006). Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immuno-globulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgRIIIa. Clin Cancer Rese, 12, 2879-87.
92. James DC, Baker KN. (2002). Glycosylation of recombinant proteins. Encyclopedia of bioprocess technology. John Wiley & Sons, Inc.
93. Jayapal K, Wlaschin K, Hu W-S, Yap M. (2007). Recombinant protein therapeutics from CHO cells-20 years and counting. CHO Consortium: SBE Special Edition, 40-7.
94. Jefferis R. (2005). Glycosylation of recombinant antibody therapeutics. Biotechnol Prog, 21, 11-16.
95. Jefferis R. (2009a). Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discovery, 8, 226-34.
96. Jefferis R. (2009b). Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci, 30, 356-62.
97. Jenkins N, Castro P, Menon S, et al. (1994). Effect of lipid supplements on the production and glycosylation of recombinant interferon-gamma expressed in CHO cells. Cytotechnology, 15, 209-15.
98. Jenkins N, Curling E. (1994). Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb Technol, 16, 354-64.
99. Jenkins N, Parekh RB, James DC. (1996). Getting the glycosylation right: Implications for the biotechnology industry. Nat Biotechnol, 14, 975-81.
100. Jeong Y, Choi O, Lim H, et al. (2008). Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransfer-ase expression. J Microbiol Biotechnol, 18, 1945.
101. Jin C, Altmann F, Strasser R, et al. (2008). A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology, 18, 235-41.
102. Jones AJS, Papac DI, Chin EH, et al. (2007). Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology, 17, 529-40.
103. Kamoda S, Kakehi K. (2006). Capillary electrophoresis for the analysis of glycoprotein pharmaceuticals. Electrophoresis, 27, 2495-504.
104. Kanda Y, Yamada T, Mori K, et al. (2007). Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology, 17, 104-18.
105. Kaneko Y, Nimmerjahn F, Ravetch JV. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670-3.
106. Kaneko Y, Sato R, Aoyagi H. (2010). Changes in the quality of antibodies produced by Chinese hamster ovary cells during the death phase of cell culture. J Biosci Bioeng, 109, 281-7.
107. Kang P, Mechref Y, Novotny MV. (2008). High-throughput solid-phase permethylation of glycans prior to mass spectrometry. Rapid Commun Mass Spectrom, 22, 721-34.
108. Kim YK, Shin HS, Tomiya N, et al. (2005). Production and N-glycan analysis of secreted human erythropoietin glycoprotein in stably transfected Drosophila S2 cells. Biotechnol Bioeng, 92, 452-61.
109. 2. Biotechnol Prog, 13, 311-17.
110. Kirkpatrick RB, Ganguly S, Angelichio M, et al. (1995). Heavy chain dimers as well as complete antibodies are efficiently formed and secreted from drosophila via a BiP-mediated pathway. J Biol Chem, 270, 19800-5.
111. Kompella A, Lee V. (1991). Pharmacokinetics of peptide and protein drugs. In: Lee V, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 391-484.
112. Kornfeld R, Kornfeld S. (1985). Assembly of asparagine-linked oligo-saccharides. Annu Rev Biochem, 54, 631-64.
113. Kost TA, Condreay JP, Jarvis DL. (2005). Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol, 23, 567-75.
114. Kumpel B, Rademacher T, Rook G, et al. (1994). Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas, 5, 143-51.
115. Kunkel JP, Jan DC, Butler M, Jamieson JC. (2000). Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors. Biotechnol Prog, 16, 462-70.
116. Kunkel JP, Jan DC, Jamieson JC, Butler M. (1998). Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol, 62, 55-71.
117. Küster B, Krogh T, Mørtz E, Harvey D. (2001). Glycosylation analysis of gel-separated proteins. Proteomics, 1, 350-61.
118. Lam JS, Huang H, Levitz SM. (2007). Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS One, 2, e1009.
119. Lamotte D, Buckberry L, Monaco L, et al. (1999). Na-butyrate increases the production and a2, 6-sialylation of recombinant interferon-g expressed by a2, 6-sialyltransferase engineered CHO cells. Cytotechnology, 29, 55-64.
120. Larsen MR, Højrup P, Roepstorff P. (2005). Characterization of gelseparated glycoproteins using two-step proteolytic digestion combined with sequential microcolumns and mass spectrometry. Mol Cell Proteom, 4, 107-19.
121. LeFloch F, Tessier B, Chenuet S, et al. (2006). Related effects of cell adaptation to serum-free conditions on murine EPO production and glycosylation by CHO cells. Cytotechnology, 52, 39-53.
122. Li H, d'Anjou M. (2009). Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol, 20, 678-84.
123. Li H, Sethuraman N, Stadheim TA, Zha D, et al. (2006). Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotech, 24, 210-15.
124. Liang M, Guttieri M, Lundkvist A, Schmaljohn C. (1997). Baculovirus expression of a human g2-specific, neutralizing igg monoclonal antibody to puumala virus. Virology, 235, 252-60.
125. Lifely MR, Hale C, Boyce S, et al. (1995). Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology, 5, 813-22.
126. Lim Y, Wong NSC, Lee YY, et al. (2010). Engineering mammalian cells in bioprocessing-current achievements and future perspectives. Biotechnol Appl Biochem, 55, 175-89.
127. Lin Z, Lo A, Simeone DM, et al. (2012). An N-glycosylation analysis of human alpha-2-macroglobulin using an integrated approach. J Proteom Bioinf, 5, 124-34.
128. Lipscomb ML, Palomares LA, Hernández V, et al. (2005). Effect of production method and gene amplification on the glycosylation pattern of a secreted reporter protein in CHO cells. Biotechnol Prog, 21, 40-9.
129. Lis H, Sharon N. (1993). Protein glycosylation. Eur J Biochem, 218, 1-27.
130. Liu C-H, Chang T-Y. (2006). Rational development of serum-free medium for Chinese hamster ovary cells. Proc Biochem, 41, 2314-19.
131. Lowe JB, Marth JD. (2003). A genetic approach to mammalian glycan function. Annu Rev Biochem, 72, 643-91.
132. Lund J, Takahashi N, Nakagawa H, et al. (1993). Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol, 30, 741-8.
133. Luong M, Lam JS, Chen J, Levitz SM. (2007). Effects of fungal N-and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine, 25, 4340-4.
134. Manzi A, Varki A. (1993). Compositional analysis of glycoproteins. In: Fukuda M, Kobata A, eds. Glycobiology: A Practical Approach. Oxford, UK: IRI Press, 27-77.
135. Marchal I, Jarvis DL, Cacan R, Verbert A. (2001). Glycoproteins from insect cells: sialylated or not? Biol Chem, 382, 151-9.
136. Marino K, Bones J, Kattla JJ, Rudd PM. (2010). A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol, 6, 713-23.
137. Marth J. (1999). N-Glycans. In: Varki A, Cummings R, Esko J, et al, eds. Essentials of Glycobiology. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
138. Masuda K, Kubota T, Kaneko E, et al. (2007). Enhanced binding affinity for FcgRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol, 44, 3122-31.
139. Matsumiya S, Yamaguchi Y, Saito J-I, et al. (2007). Structural comparison of fucosylated and nonfucosylated fc fragments of human immunoglobulin G1. J Mol Biol, 368, 767-79.
140. Merry AH, Neville DCA, Royle L, et al. (2002). Recovery of intact 2-aminobenzamide-labeled o-glycans released from glycoproteins by hydrazinolysis. Anal Biochem, 304, 91-9.
141. Merry TH, Royle L, Radcliffe CM, et al. (2004). Analysis of N-and O-linked glycans of glycoproteins. Encyclopedia of genetics, gen-omics, proteomics and bioinformatics. Chichester, UK: John Wiley & Sons, Ltd.
142. Mimura Y, Jefferis R, Mimura-Kimura Y, et al. (2009). Glycosylation of therapeutic IgGs. Therapeutic monoclonal antibodies. Hoboken, NJ: John Wiley & Sons, Inc., 67-89.
143. Mimura Y, Lund J, Church S, et al. (2001). Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform profile. J Immunol Meth, 247, 205-16.
144. Morell AG, Gregoriadis G, Scheinberg IH, et al. (1971). The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem, 246, 1461-7.
145. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, et al. (2004). Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng, 88, 901-8.
146. Müthing J, Kemminer SE, Conradt HS, et al. (2003). Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng, 83, 321-34.
147. Nabi IR, Dennis JW. (1998). The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. Glycobiology, 8, 947-53.
148. Nahrgang S, Kragten E, De Jesus M, et al. (1999). The effect of cell line, transfection procedure and reactor conditions on the glycosylation of recombinant human anti-rhesus D IGG1. In: Bernard A, ed. Animal Cell Technology: Products from Cells, Cells as Products. Proceedings of the ESACT Meeting, 16th, Lugano; Apr 25-29; Switzerland, 259-61.
149. Narhi LO, Arakawa T, Aoki KH, et al. (1991). The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem, 266, 23022-6.
150. Natsume A, Niwa R, Satoh M. (2009). Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Dev Ther, 3, 7-16.
151. Niklas J, Schräder E, Sandig V, Noll T, Heinzle E. (2011). Quantitative characterization of metabolism and metabolic shifts during growth of the new human cell line AGE1.HN using time resolved metabolic flux analysis. Bioproc Biosys Eng, 34, 533-45.
152. Nyberg GB, Balcarcel RR, Follstad BD, et al. (1999). Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol Bioeng, 62, 336-47.
153. Omasa T, Tanaka R, Doi T, et al. (2008). Decrease in antithrombin III fucosylation by expressing GDP-fucose transporter siRNA in Chinese hamster ovary cells. J Biosci Bioeng, 106, 168-73.
154. Osborne C, Brooks SA. (2006). SDS-PAGE and Western blotting to detect proteins and glycoproteins of interest in breast cancer research. Method Mol Med, 120, 217-29.
155. Ozturk SS, Hu W-S. (2006). Cell culture technology for pharmaceutical and cell-based therapies. New York: CRC Press.
156. Padler-Karavani V, Yu H, Cao H, et al. (2008). Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology, 18, 818-30.
157. Patel T, Parekh R, Moellering B, Prior C. (1992). Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochemical J, 285, 839-45.
158. Patwa T, Li C, Simeone DM, Lubman DM. (2010). Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom Rev, 29, 830-44.
159. Perlman S, van den Hazel B, Christiansen J, et al. (2003). Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrin Metabol, 88, 3227-35.
160. Peterman S, Mulholland J. (2006). A novel approach for identification and characterization of glycoproteins using a hybrid linear ion trap/FT-ICR mass spectrometer. J Am Soc Mass Spectrom, 17, 168-79.
161. Pilobello KT, Slawek DE, Mahal LK. (2007). A ratiometric lectin microarray approach to analysis of the dynamic mammalian glycome. Proc Nat Acad Sci, 104, 11534-9.
162. Preithner S, Elm S, Lippold S, et al. (2006). High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol, 43, 1183-93.
163. Raju TS. (2003). Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProc Int, 1, 44-53.
164. Raju TS. (2008). Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol, 20, 471-8.
165. Raju TS, Scallon B. (2007). Fc glycans terminated with N-acetylgluco-samine residues increase antibody resistance to papain. Biotechnol Prog, 23, 964-71.
166. Rearick JI, Chapman A, Kornfeld S. (1981). Glucose starvation alters lipid-linked oligosaccharide biosynthesis in Chinese hamster ovary cells. J Biol Chem, 256, 6255-61.
167. Restelli V, Butler M. (2002). The effect of cell culture parameters on protein glycosylation. In: Al-Rubeai M, ed. Glycosylation. Dordrecht: Kluwer Publishers, 61-92.
168. Reuter G, Gabius H. (1999). Eukaryotic glycosylation: whim of nature or multipurpose tool? Cell and Mol Life Sci, 55, 368-422.
169. Rodriguez J, Spearman M, Huzel N, Butler M. (2005). Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions. Biotechnol Prog, 21, 22-30.
170. Roth Z, Yehezkel G, Khalaila I. (2012). Identification and quantification of protein glycosylation. Int J Carbohydr Chem, 2012, 1-10.
171. Rothman RJ, Warren L, Vliegenthart JFG, Hard KJ. (1989). Clonal analysis of the glycosylation of immunoglobulin G secreted by murine hybridomas. Biochemistry, 28, 1377-84.
172. Royle L, Dwek RA, Rudd PM. (2001). Determining the structure of oligosaccharides N-and O-linked to glycoproteins. Current protocols in protein science. Hoboken, NJ: John Wiley & Sons, Inc.
173. Royle L, Mattu TS, Hart E, et al. (2002). An analytical and structural database provides a strategy for sequencing O-glycans from microgram quantities of glycoproteins. Anal Biochem, 304, 70-90.
174. Royle L, Radcliffe CM, Dwek RA, Rudd PM. (2007). Detailed structural analysis of n-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. In: Brockhausen I, ed. Glycobiology protocols. Totowa, NJ: Humana Press, 125-43.
175. Runkel L, Meier W, Pepinsky RB, et al. (1998). Structural and Functional differences between glycosylated and non-glycosylated forms of human interferon-b (IFN-b). Pharm Res, 15, 641-9.
176. Ryll T, Dutina G, Reyes A, et al. (2000). Performance of small-scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: characterization of separation efficiency and impact of perfusion on product quality. Biotechnol Bioeng, 69, 440-9.
177. Sareneva T, Cantell K, Pyhälä L, et al. (1993). Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. J Interferon Res, 13, 267-9.
178. Sareneva T, Mørtz E, Tölö H, et al. (1996). Biosynthesis and N-glycosylation of human interferon-g. Eur J Biochem, 242, 191-200.
179. Sasaki H, Bothner B, Dell A, Fukuda M. (1987). Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem, 262, 12059-76.
180. Satoh M, Iida S, Shitara K. (2006). Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther, 6, 1161-73.
181. Scallon BJ, Tam SH, McCarthy SG, et al. (2007). Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol, 44, 1524-34.
182. Schräder E, Scholz S, Niklas J, et al. (2011). Characterisation of cultivation of the human cell line AGE1.HN.AAT. BMC Proceedings, 5, 1-2.
183. Schumann W, Ferreira LCS. (2004). Production of recombinant proteins in Escherichia coli. Gen Mol Biol, 27, 442-53.
184. Schuster M, Umana P, Ferrara C, et al. (2005). Improved effector functions of a therapeutic monoclonal lewis y-specific antibody by glycoform engineering. Cancer Res, 65, 7934-41.
185. Sethuraman N, Stadheim TA. (2006). Challenges in therapeutic glyco-protein production. Curr Opin Biotechnol, 17, 341-6.
186. Sheeley DM, Merrill BM, Taylor LCE. (1997). Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal a-linked galactose. Anal Biochem, 247, 102-10.
187. Shelikoff M, Sinskey AJ, Stephanopoulos G. (1994). The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin. Cytotechnology, 15, 195-208.
188. Shields RL, Lai J, Keck R, et al. (2002). Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem, 277, 26733-40.
189. Shinkawa T, Nakamura K, Yamane N, et al. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylgluco-samine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem, 278, 3466-73.
190. Sinclair AM, Elliott S. (2005). Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci, 94, 1626-35.
191. Smalling R, Foote M, Molineux G, et al. (2004). Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol Ann Rev, 10, 237-50.
192. Soderquist RG, Lee JM. (2005). Enhanced production of recombinant proteins from plant cells by the application of osmotic stress and protein stabilization. Plant Cell Rep, 24, 127-32.
193. Solá RJ, Griebenow K. (2009). Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci, 98, 1223-45.
194. Sondermann P, Kaiser J, Jacob U. (2001). Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol, 309, 737-49.
195. Spearman M, Rodriguez J, Huzel N, Butler M. (2005). Production and glycosylation of recombinant b-interferon in suspension and cytopore microcarrier cultures of CHO cells. Biotechnol Prog, 21, 31-9.
196. Stark N, Heath E. (1979). Glucose-dependent glycosylation of secretory glycoprotein in mouse myeloma cells. Arch Biochem Biophys, 192, 599-609.
197. Strasser R, Stadlmann J, Schähs M, et al. (2008). Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J, 6, 392-402.
198. Sung YH, Song YJ, Lim SW, et al. (2004). Effect of sodium butyrate on the production, heterogeneity and biological activity of human thrombopoietin by recombinant Chinese hamster ovary cells. J Biotechnol, 112, 323-35.
199. Swiech K, Picanço-Castro V, Covas DT. (2012). Human cells: new platform for recombinant therapeutic protein production. Protein Expr Purif, 84, 147-53.
200. Tarelli E. (2007). Glycosylation of medicinal products. Medicines from animal cell culture. Chichester, UK: John Wiley & Sons, Ltd., 479-90.
201. Taverna M, Tran NT, Merry T, et al. (1998). Electrophoretic methods for process monitoring and the quality assessment of recombinant glycoproteins. Electrophoresis, 19, 2572-94.
202. Taylor ME, Drickamer K. (2006). Introduction to glycobiology. Oxford, USA: Oxford University Press.
203. Townsend R, Stahl P. (1981). Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. Biochem J, 194, 209-14.
204. Townsend RR, Hardy MR. (1991). Analysis of glycoprotein oligosac-charides using high-pH anion exchange chromatography. Glycobiology, 1, 139-47.
205. Tran NT, Taverna M, Merry AH, et al. (2000). A sensitive mapping strategy for monitoring the reproducibility of glycan processing in an HIV vaccine, RGP-160, expressed in a mammalian cell line. Glycoconjugate J, 17, 401-6.
206. Tretter V, Altmann F, März L. (1991). Peptide-N4-(N-acetyl-b-glucosaminyl)asparagine amidase F cannot release glycans with fucose attached a1 ! 3 to the asparagine-linked N-acetylglucosamine residue. Eur J Biochem, 199, 647-52.
207. Trummer E, Fauland K, Seidinger S, et al. (2006a). Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol Bioeng, 94, 1033-44.
208. Trummer E, Fauland K, Seidinger S, et al. (2006b). Process parameter shifting: Part II. Biphasic cultivation-a tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells. Biotechnol Bioeng, 94, 1045-52.
209. Umana P, Jean-Mairet J, Moudry R, et al. (1999). Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotech, 17, 176-80.
210. Valley U, Nimtz M, Conradt HS, Wagner R. (1999). Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. Biotechnol Bioeng, 64, 401-17.
211. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. (1998). Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol, 33, 151-208.
212. van Kasteren SI, Kramer HB, Jensen HH, et al. (2007). Expanding the diversity of chemical protein modification allows post-translational mimicry. Nature, 446, 1105-9.
213. Voisard D, Meuwly F, Ruffieux PA, et al. (2003). Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng, 82, 751-65.
214. Vugmeyster Y, Howell K. (2004). Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharm, 4, 1117-24.
215. Wada Y, Gu J, Okamoto N, Inui K. (1994). Diagnosis of carbohydrate-deficient glycoprotein syndrome by matrix-assisted laser desorption time-of-flight mass spectrometry. Biol Mass Spectrom, 23, 108-9.
216. Waegeman H, Mey MD. (2012). Increasing recombinant protein production in E. coli by an alternative method to reduce acetate. In: Petre M, ed. Advances in Applied Biotechnology. In-Tech, 127-44.
217. Walsh G. (2010). Biopharmaceutical benchmarks 2010. Nat Biotech, 28, 917-24.
218. Walsh G, Jefferis R. (2006). Post-translational modifications in the context of therapeutic proteins. Nat Biotech, 24, 1241-52.
219. Wang L-X. (2008). Chemoenzymatic synthesis of glycopeptides and glycoproteins through endoglycosidase-catalyzed transglycosylation. Carbohydr Res, 343, 1509-22.
220. Wang L-X, Lomino JV. (2011). Emerging technologies for making glycan-defined glycoproteins. ACS Chem Biol, 7, 110-22.
221. Wang WC, Lee N, Aoki D, et al. (1991). The poly-N-acetyllactosamines attached to lysosomal membrane glycoproteins are increased by the prolonged association with the Golgi complex. J Biol Chem, 266, 23185-90.
222. Wang Y, Wu S-l, Hancock WS. (2006). Monitoring of glycoprotein products in cell culture lysates using lectin affinity chromatography and capillary HPLC coupled to electrospray linear ion trap-Fourier transform mass spectrometry (LTQ/FTMS). Biotechnol Prog, 22, 873-80.
223. Watson E, Shah B, Leiderman L, et al. (1994). Comparison of N-linked oligosaccharides of recombinant human tissue kallikrein produced by Chinese hamster ovary cells on microcarrier beads and in serum-free suspension culture. Biotechnol Prog, 10, 39-44.
224. Wei Y, Li C, Huang W, et al. (2008). Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation. Biochemistry, 47, 10294-304.
225. Weigel PH, Yik JHN. (2002). Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta, Gen Subj, 1572, 341-63.
226. Weikert S, Papac D, Briggs J, et al. (1999). Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycopro-teins. Nat Biotech, 17, 1116-21.
227. Wileman T, Harding C, Stahl P. (1985). Receptor-mediated endocytosis. Biochem J, 232, 1-14.
228. Wilson NL, Schulz BL, Karlsson NG, Packer NH. (2002). Sequential analysis of N-and O-linked glycosylation of 2D-PAGE separated glycoproteins. J Proteome Res, 1, 521-9.
229. Wong CFD, Wong TKK, Goh TL, et al. (2005). Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng, 89, 164-77.
230. Wopereis S, Lefeber DJ, Morava E, Wevers RA. (2006). Mechanisms in protein o-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin Chem, 52, 574-600.
231. Wuhrer M, Catalina MI, Deelder AM, Hokke CH. (2007). Glycoproteomics based on tandem mass spectrometry of glycopep-tides. J Chromatogr B, 849, 115-28.
232. Wuhrer M, Koeleman CAM, Hokke CH, Deelder AM. (2004). Protein glycosylation analyzed by normal-phase nano-liquid chromatography-mass spectrometry of glycopeptides. Anal Chem, 77, 886-94.
233. Wurm FM. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol, 22, 1393-8.
234. Yamane-Ohnuki N, Kinoshita S, Miho I-U, et al. (2004). Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng, 87, 614-22.
235. Yamane-Ohnuki N, Satoh M. (2009). Production of therapeutic antibodies with controlled fucosylation. MAbs, 1, 230-6.
236. Yang J-D, Angelillo Y, Chaudhry M, et al. (2000). Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. Biotechnol Bioeng, 69, 74-82.
237. Yang M, Butler M. (2000a). Effect of ammonia on the glycosylation of human recombinant erythropoietin in culture. Biotechnol Prog, 16, 751-9.
238. Yang M, Butler M. (2000b). Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation. Biotechnol Bioeng, 68, 370-80.
239. Yang M, Butler M. (2002). Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog, 18, 129-38.
240. Yoon SK, Choi SL, Song JY, Lee GM. (2005). Effect of culture pH on erythropoietin production by Chinese hamster ovary cells grown in suspension at 32.5 and 37.0°C. Biotechnol Bioeng, 89, 345-56.
241. Yoon SK, Song JY, Lee GM. (2003). Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol Bioeng, 82, 289-98.
242. Yuen C, Storring P, Tiplady R, et al. (2003). Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Brit J Haematol, 121, 511-26.
243. 2 or pH. Biotechnol Bioeng, 65, 182-91.
244. Zhang F, Murhammer D, Linhardt R. (2002). Enzyme kinetics and glycan structural characterization of secreted alkaline phosphatase prepared using the baculovirus expression vector system. Appl Biochem Biotechnol, 101, 197-210.
245. Zhang J. (2010). Mammalian cell culture for biopharmaceutical production. In: Baltz RH, ed. Manual of Industrial Microbiology and Biotechnology. 3rd ed. Washington, DC: American Society of Microbiology. 157-78.
246. Zhao F-Q, Keating AF. (2007). Functional properties and genomics of glucose transporters. Curr Genomics, 8, 113-28.
247. Zhou Q, Shankara S, Roy A, et al. (2008). Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng, 99, 652-65.
248. Zhu J. (2011). Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv, 30, 1158-70.
249. Zhu Y, Li X, Mcvie-Wylie A, et al. (2005). Carbohydrate-remodelled acid a-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J, 389, 619-28.
250. Zou G, Ochiai H, Huang W, et al. (2011). Chemoenzymatic synthesis and Fcg receptor binding of homogeneous glycoforms of antibody Fc domain. presence of a bisecting sugar moiety enhances the affinity of Fc to FcgIIIa receptor. J Am Chem Soc, 133, 18975-91.